-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PEG-irinotecan in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEG-irinotecan in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEG-irinotecan in Metastatic Breast Cancer Drug Details: PEG-Irinotecan is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sodium Benzoate in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sodium Benzoate in Schizophrenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sodium Benzoate in Schizophrenia Drug Details: Sodium benzoate (SND-1, SB-01, SR-01) is...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNG-12 in Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNG-12 in Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNG-12 in Depression Drug Details: SNG-12 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SNA-11 in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNA-11 in Treatment Resistant Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SNA-11 in Treatment Resistant Depression Drug Details:SNA-11 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FAZ-053 in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FAZ-053 in Soft Tissue Sarcoma Drug Details: FAZ-053 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-968 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XmAb-968 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.XmAb-968 in Refractory Acute Myeloid Leukemia Drug Details:XmAb-698 (AMG-424) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-397 in Adenoid Cystic Carcinoma (ACC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-397 in Adenoid Cystic Carcinoma (ACC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-397 in Adenoid Cystic Carcinoma (ACC) Drug Details: IDE397...